Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study

NCT03346824 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2018-02-27

No results posted yet for this study

Summary

Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.

Conditions

  • Cardiogenic Shock

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346824 on ClinicalTrials.gov